Biosimilars of infliximab (CT-P13) are currently approved and available for the
same indications as for the originator. Some concerns about safety and immunogenicity have
risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been
conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the
originator, both in adult and pediatric population, either in naïve patients or even in those who
switched from the originator to CT-P13. This review aims to analyze the current literature
data in order to define a clear patient profile, to identify those IBD patients who would benefit
the most from the use of CT-P13.
Keywords: Infliximab, biosimilar, CT-P13, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.
Rights & PermissionsPrintExport